SJS/TEN 2019: From science to translation

White, 2018, SJS/TEN 2017: building multidisciplinary networks to drive science and translation, J. Allergy Clin. Immunol. Pract., 6, 38, 10.1016/j.jaip.2017.11.023 Mallal, 2008, HLA-B*5701 screening for hypersensitivity to abacavir, N. Engl. J. Med., 358, 568, 10.1056/NEJMoa0706135 Chen, 2011, Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan, N. Engl. J. Med., 364, 1126, 10.1056/NEJMoa1009717 Zhang, 2013, HLA-B*13:01 and the dapsone hypersensitivity syndrome, N. Engl. J. Med., 369, 1620, 10.1056/NEJMoa1213096 Ko, 2015, Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study, BMJ, 351, h4848, 10.1136/bmj.h4848 Manolio, 2018, Research directions in genetic predispositions to Stevens-Johnson syndrome/toxic epidermal necrolysis, Clin. Pharmacol. Ther., 103, 390, 10.1002/cpt.890 Le, 2016, Burn unit care of Stevens Johnson syndrome/toxic epidermal necrolysis: a survey, Burns, 42, 830, 10.1016/j.burns.2015.12.001 Lim, 2016, A decade of burn unit experience with Stevens-Johnson syndrome/toxic epidermal necrolysis: clinical pathological diagnosis and risk factor awareness, Burns, 42, 836, 10.1016/j.burns.2016.01.014 Garcia-Doval, 2000, Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death?, Arch. Dermatol., 136, 323, 10.1001/archderm.136.3.323 González-Herrada, 2017, Cyclosporine use in epidermal necrolysis is associated with an important mortality reduction: evidence from three different approaches, J. Invest. Dermatol., 137, 2092, 10.1016/j.jid.2017.05.022 Wang, 2018, Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions, J. Clin. Invest., 128, 985, 10.1172/JCI93349 McPherson, 2019, British Association of Dermatologists’ guidelines for the management of Stevens–Johnson syndrome/toxic epidermal necrolysis in children and young people, 2018, Br. J. Dermatol., 181, 37, 10.1111/bjd.17841 Schwartz, 2013, Toxic epidermal necrolysis: part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment, J. Am. Acad. Dermatol., 69, 187, 10.1016/j.jaad.2013.05.002 Meneux, 1998, Vulvovaginal involvement in toxic epidermal necrolysis: a retrospective study of 40 cases, Obstet. Gynecol., 91, 283, 10.1016/S0029-7844(97)00596-6 Niemeijer, 2009, Relevance and consequences of erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in gynecology, Arch. Gynecol. Obstet., 280, 851, 10.1007/s00404-009-1008-1 Gregory, 2016, New grading system and treatment guidelines for the acute ocular manifestations of Stevens-Johnson syndrome, Ophthalmology, 123, 1653, 10.1016/j.ophtha.2016.04.041 Kohanim, 2016, Acute and chronic ophthalmic involvement in Stevens-Johnson syndrome/toxic epidermal necrolysis -- a comprehensive review and guide to therapy. II. Ophthalmic disease, Ocul. Surf., 14, 168, 10.1016/j.jtos.2016.02.001 Sharma, 2016, Adjuvant role of amniotic membrane transplantation in acute ocular Stevens–Johnson syndrome, Ophthalmology, 123, 484, 10.1016/j.ophtha.2015.10.027 Shanbhag, 2019, Long-term impact of a treatment protocol for acute ocular involvement in Stevens-Johnson syndrome/toxic epidermal necrolysis, Am. J. Ophthalmol., 208, 331, 10.1016/j.ajo.2019.07.006 Ueta, 2014, Trans-ethnic study confirmed independent associations of HLA-A*02:06 and HLA-B*44:03 with cold medicine-related Stevens-Johnson syndrome with severe ocular surface complications, Sci. Rep., 4, 5981, 10.1038/srep05981 Roujeau, 2018, Epidermal necrolysis, ocular complications, and “Cold Medicines”, J. Allergy Clin. Immunol. Pract., 6, 703, 10.1016/j.jaip.2017.10.033 Ueta, 2018, Results of detailed investigations into Stevens-Johnson syndrome with severe ocular complications, Invest. Ophthalmol. Vis. Sci., 59, DES183, 10.1167/iovs.17-23537 Blumenthal, 2015, Stevens-Johnson syndrome and toxic epidermal necrolysis: a cross-sectional analysis of patients in an integrated allergy repository of a large health care system, J. Allergy Clin. Immunol. Pract., 3, 277, 10.1016/j.jaip.2014.10.002 Wong, 2019, Drug hypersensitivity reactions documented in electronic health records within a large health system, J. Allergy Clin. Immunol. Pract., 7, 1253, 10.1016/j.jaip.2018.11.023 European Medicines Agency (EMA)/Pharmacovigilance Risk Assessment Committee (PRAC) recommendations on safety signals- List of safety signals discussed since September 2012, (2012). https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/signal-management/prac-recommendations-safety-signals#list-of-safety-signals-discussed-since-september-2012-section. Tan-Koi, 2017, Tailoring of recommendations to reduce serious cutaneous adverse drug reactions: a pharmacogenomics approach, Pharmacogenomics, 18, 881, 10.2217/pgs-2017-0016 Sassolas, 2010, ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis, Clin. Pharmacol. Ther., 88, 60, 10.1038/clpt.2009.252 Amstutz, 2014, Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions, Epilepsia, 55, 496, 10.1111/epi.12564 Chung, 2014, Genetic variants associated with phenytoin-related severe cutaneous adverse reactions, JAMA, 312, 525, 10.1001/jama.2014.7859 Chen, 2017, Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in Asians, Neurology, 88, 78, 10.1212/WNL.0000000000003453 Konvinse, 2019, HLA-A*32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms, J. Allergy Clin. Immunol., 144, 183, 10.1016/j.jaci.2019.01.045 Nicoletti, 2019, Shared genetic risk factors across carbamazepine-induced hypersensitivity reactions, Clin. Pharmacol. Ther., 106, 1028, 10.1002/cpt.1493 McCormack, 2018, Genetic variation in CFH predicts phenytoin-induced maculopapular exanthema in European-descent patients, Neurology, 90, e332, 10.1212/WNL.0000000000004853 Chung, 2008, Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis, Nat. Med., 14, 1343, 10.1038/nm.1884 Su, 2017, Interleukin-15 is associated with severity and mortality in Stevens-Johnson syndrome/toxic epidermal necrolysis, J. Invest. Dermatol., 137, 1065, 10.1016/j.jid.2016.11.034 Paulmann, 2017, Fever in Stevens-Johnson syndrome and toxic epidermal necrolysis in pediatric cases: laboratory work-up and antibiotic therapy, Pediatr. Infect. Dis. J., 36, 513, 10.1097/INF.0000000000001571 Peter, 2019, Drug hypersensitivity in HIV infection, Curr. Opin. Allergy Clin. Immunol., 19, 272, 10.1097/ACI.0000000000000545 Sekula, 2013, Comprehensive survival analysis of a cohort of patients with Stevens–Johnson syndrome and toxic epidermal necrolysis, J. Invest. Dermatol., 133, 1197, 10.1038/jid.2012.510 Lehloenya, 2019, Lower-than-predicted mortality in a predominantly HIV-infected population with epidermal necrolysis regardless of HIV status: implications and challenges for interventional studies, J. Allergy Clin. Immunol. Pract., 7, 1653, 10.1016/j.jaip.2018.10.053 Dodiuk-Gad, 2016, Major psychological complications and decreased health-related quality of life among survivors of Stevens-Johnson syndrome and toxic epidermal necrolysis, Br. J. Dermatol., 175, 422, 10.1111/bjd.14799 Hefez, 2019, Post-traumatic stress disorder in Stevens-Johnson syndrome and toxic epidermal necrolysis: prevalence and risk factors. A prospective study of 31 patients, Br. J. Dermatol., 180, 1206, 10.1111/bjd.17267 Olteanu, 2018, Severe physical complications among survivors of Stevens–Johnson syndrome and toxic epidermal necrolysis, Drug Saf., 41, 277, 10.1007/s40264-017-0608-0 Sheridan, 2002, Long-term consequences of toxic epidermal necrolysis in children, Pediatrics, 109, 74, 10.1542/peds.109.1.74 Paquet, 2007, Delayed reepithelialization and scarring deregulation following drug-induced toxic epidermal necrolysis, Burns, 33, 100, 10.1016/j.burns.2006.04.031 Kreft, 2014, Extensive hypertrophic scarring after toxic epidermal necrolysis in a child, Pediatr. Dermatol., 31, 527, 10.1111/j.1525-1470.2012.01863.x Anderson, 2014, Laser treatment of traumatic scars with an emphasis on ablative fractional laser resurfacing: consensus report, JAMA Dermatol., 150, 187, 10.1001/jamadermatol.2013.7761 Miletta, 2017, Management of trauma and burn scars: the dermatologist’s role in expanding patient access to care, Cutis, 100, 18 Chung, 2015, Oxypurinol-specific T cells possess preferential TCR clonotypes and express granulysin in allopurinol-induced severe cutaneous adverse reactions, J. Invest. Dermatol., 135, 2237, 10.1038/jid.2015.165 Pan, 2019, Identification of drug-specific public TCR driving severe cutaneous adverse reactions, Nat. Commun., 10, 3569, 10.1038/s41467-019-11396-2 Cardone, 2018, A transgenic mouse model for HLA-B*57:01-linked abacavir drug tolerance and reactivity, J. Clin. Invest., 128, 2819, 10.1172/JCI99321